Associated Papers
Pharmacogenetic study of CES1 gene and enalapril efficacy.
Hussain M et al.
Journal of Applied Genetics, 2024
Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis C.
Loucks CM et al.
Liver International : Official Journal of the International Association for the Study of the Liver, 2022
Clinical implications of genetic variation in carboxylesterase drug metabolism.
Chen F et al.
Expert Opinion on Drug Metabolism & Toxicology, 2018
The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans.
Oh J et al.
Plos One, 2017
Population Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants.
Lyauk YK et al.
Clinical and Translational Science, 2016
CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.
Wang X et al.
The Pharmacogenomics Journal, 2016
How well do whole exome sequencing results correlate with medical findings? A study of 89 Mayo Clinic Biobank samples.
Middha S et al.
Frontiers in Genetics, 2015
26257771 (PubMed )
Supplement: Table12.XLSX › snv.tier2
Pharmacodynamic Impact of Carboxylesterase 1 Gene Variants in Patients with Congestive Heart Failure Treated with Angiotensin-Converting Enzyme Inhibitors.
Nelveg-Kristensen KE et al.
Plos One, 0
Select a paper to view details